Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Startup Parabilis Medicines has raised $305 million in new funding, money that will help bring its lead drug for a variety of ...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that ...

US biotech Aktis Oncology has filed IPO documents with the Securities and Exchange Commission (SEC), in what could be the ...

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are ...

Term Sheet readers sounded off on how they think the state of exits in the private markets will evolve through 2026.

Poplar Therapeutics Inc. launched on Wednesday capitalized with $50 million Series A financing and led by Chip Baird, the ...

Nimbus Therapeutics LLC is going to work with Eli Lilly to develop a new oral drug for obesity, joining the spate of deals ...

China's biotech revival is pushing up prices of laboratory monkeys used in drug testing, as renewed R&D activity collides ...